A US Food and Drug Advisory (FDA) panel has voted 10 to 1 in favor of approval for AstraZeneca and Bristol-Myers Squibb’s diabetes drug dapagliflozin (Medscape)
Diabetes News Service
A US Food and Drug Advisory (FDA) panel has voted 10 to 1 in favor of approval for AstraZeneca and Bristol-Myers Squibb’s diabetes drug dapagliflozin (Medscape)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales